What is the history of Retinitis pigmentosa?

TL;DR: Retinitis pigmentosa was first formally described in the mid-19th century by Dutch ophthalmologist Franciscus Donders, who coined the term to reflect the characteristic pigmentary deposits observed in the retina. Since then, our understanding has evolved from a vague "degeneration" to a complex group of over 100 genetically distinct inherited retinal diseases, moving from purely descriptive observation to gene-based therapeutic interventions.

When was Retinitis pigmentosa first described?

While reports of night blindness (nyctalopia) date back to ancient medical texts, Retinitis pigmentosa was first clearly characterized as a distinct clinical entity in 1857 by Franciscus Donders. Shortly after the invention of the ophthalmoscope by Hermann von Helmholtz in 1851, physicians were finally able to peer inside the living eye. Donders observed the "bone-spicule" pigment patterns that are now considered a hallmark of Retinitis pigmentosa. Early researchers initially believed the condition was an inflammatory process, which is why the term "retinitis" was used, though we now know the disease is primarily a progressive, non-inflammatory degeneration of photoreceptor cells.

How has our understanding of Retinitis pigmentosa evolved?

For nearly a century, Retinitis pigmentosa was viewed as a singular, mysterious condition. It was not until the mid-20th century that the hereditary nature of the disease was systematically mapped. Researchers began to distinguish between various inheritance patterns, including autosomal dominant, autosomal recessive, and X-linked forms. Today, we understand that Retinitis pigmentosa is not one disease, but a heterogeneous collection of conditions caused by mutations in over 80 different genes involved in the visual cycle, photoreceptor structure, and retinal metabolism.

What were the major milestones in research and treatment?

The journey from observation to potential treatment has been marked by several critical technological breakthroughs:

• 1857: First clinical description of Retinitis pigmentosa by Donders.


• 1980s-90s: The advent of molecular genetics allowed for the identification of the first specific gene mutations (such as RHO) responsible for the condition.


• 2013: The Argus II retinal prosthesis received FDA approval as the first bionic eye, offering a way to restore some functional vision for those with profound Retinitis pigmentosa.


• 2017: The FDA approved voretigene neparvovec-rzyl (Luxturna), the first gene therapy for an inherited retinal disease, marking a paradigm shift in how we approach Retinitis pigmentosa.

How has patient advocacy changed the landscape?

Historically, patients diagnosed with Retinitis pigmentosa were often told there was "nothing to be done," leading to significant social isolation. The rise of global advocacy groups—such as the Foundation Fighting Blindness—transformed the patient experience. By funding research and creating registries, these groups have accelerated clinical trials and provided a platform for the 707 members currently connected through DiseaseMaps.org to share their lived experiences and emotional support, moving the community from passive observation to active participation in scientific discovery.

Next steps

• Consult a board-certified retina specialist for a comprehensive dilated eye exam and high-resolution imaging (OCT).


• Seek a referral to a clinical geneticist or genetic counselor to discuss genetic testing, which can identify the specific mutation type and potential eligibility for clinical trials.


• Join the DiseaseMaps.org community to connect with others sharing similar journeys and to stay updated on the latest research developments.

Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding your specific condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD): Retinitis pigmentosa overview.


• Orphanet: Rare disease database entry for Retinitis pigmentosa.


• OMIM (Online Mendelian Inheritance in Man): Comprehensive catalog of genes associated with Retinitis pigmentosa.


• Foundation Fighting Blindness: History of research and community advocacy for inherited retinal diseases.